Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the earnings call transcript. The company reported a gross debt of Rs.170 crores and cash & cash equivalents of Rs.240 crores as of June 30, 2024, maintaining a net debt-free position. For the Rajasthan project (a potential large opportunity), vendor financing commitments from OEM manufacturers exist, enabling deployment of equipment with limited cash outflow and no immediate large capital expenditure required from company reserves. The company plans CAPEX of Rs.170 crores for FY25, with Rs.22 cror

Any current/future capex/capital investment/strategic investment?

Planned CAPEX for FY25 is Rs.170 crores, with Rs.22 crores already spent in Q1. CAPEX is mainly focused on radiology projects in Maharashtra and Madhya Pradesh, including deployment of CT scans and MRIs. Maharashtra plans include operationalizing 21 CT centers with another 18 soon, plus installing seven more CT machines and five MRIs by year-end. Madhya Pradesh MRI project involves installing five MRIs; two centers expected operational by year-end. Vendor financing arrangements are in place for Rajasthan tender equipment, enabling asset deployment with minimal immediate cash outgo. Retail expa

Future growth expectations in sales/revenue/volumes?

Krsnaa Diagnostics aims for a base revenue growth of 25% with an aspirational target of around 30% by FY25 end. Q1 FY25 revenue reached Rs.170 crores, showing a 22% YoY increase, indicating strong momentum. The company plans to expand retail operations over the next 6-12 months, which is expected to stabilize and add to margin and revenue growth. Punjab is on a continued growth trajectory with increasing month-on-month volumes. Projects like MRI and CT deployments in Maharashtra and other states are expected to increase volumes during FY25. Potential Rajasthan tender, if awarded, cou

Future growth expectations in earnings/operating earnings/profits/EPS?

Krsnaa Diagnostics targets a base revenue growth of 25% for FY25, with an aspirational target of up to 30%. Q1 FY25 saw a 22% YoY revenue growth and a 39% YoY growth in EBITDA, indicating positive momentum. EBITDA margins are expected to improve, targeting around 25% by year-end, driven by mature PPP projects, ramp-up of new centers, and retail expansion. Retail expansion is expected to stabilize within 6-12 months and contribute positively to margins thereafter. The company anticipates the margin profile of retail operations to align with industry averages over time, despite some initial expe

Current/ Expected Orderbook/ Pending Orders?

The company is involved in several government tenders, including a significant pending Rajasthan tender with over 1,200 collection centers; operationalizing would take 9-12 months post-win. Rajasthan tender is currently under judicial review; company has fulfilled all obligations and awaits resolution. Maharashtra tender includes 21 CTs implemented in Q1 FY25; plans to deploy additional 14 CTs and 5 MRI machines this fiscal year. Other active contracts: Maharashtra (~15 years), Odisha (~12 years), Assam (~5 years), Madhya Pradesh (~12 years). Pipeline includes projects in Andhra Pradesh and So

Krsnaa Diagnost.Q1 FY25Healthcare Services

Krsnaa Diagnost. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹555P/E: 18.0Market Cap: ₹1.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Krsnaa Diagnostics aims for a base revenue growth of 25% with an aspirational target of around 30% by FY25 end.
Q1 FY25 revenue reached Rs.170 crores, showing a 22% YoY increase, indicating strong momentum.
The company plans to expand retail operations over the next 6-12 months, which is expected to stabilize and add to margin and revenue growth.
Punjab is on a continued growth trajectory with increasing month-on-month volumes.
Projects like MRI and CT deployments in Maharashtra and other states are expected to increase volumes during FY25.
Potential Rajasthan tender, if awarded, could add 300-400 crores in revenues with a 9-12 month ramp-up timeline.
Overall growth is supported by both expansion in mature PPP centers and new centers coming online, with new centers expected to improve margins gradually.
Retail foray targets to capture a large addressable market (~Rs. 40,000 crores) by leveraging existing diagnostic infrastructure without adding new franchises.

Margin guidance

Category 1

Krsnaa Diagnostics targets a base revenue growth of 25% for FY25, with an aspirational target of up to 30%.
Q1 FY25 saw a 22% YoY revenue growth and a 39% YoY growth in EBITDA, indicating positive momentum.
EBITDA margins are expected to improve, targeting around 25% by year-end, driven by mature PPP projects, ramp-up of new centers, and retail expansion.
Retail expansion is expected to stabilize within 6-12 months and contribute positively to margins thereafter.
The company anticipates the margin profile of retail operations to align with industry averages over time, despite some initial expenses.
Profit after tax (PAT) showed a healthy 14% growth in Q1 FY25 compared to Q4 FY24, reflecting improving operational efficiency.
The company remains net debt-free, supporting sustained growth funding and operational stability.

See what Krsnaa Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned new fundraising through debt or equity in the earnings call transcript.
The company reported a gross debt of Rs.170 crores and cash & cash equivalents of Rs.240 crores as of June 30, 2024, maintaining a net debt-free position.
For the Rajasthan project (a potential large opportunity), vendor financing commitments from OEM manufacturers exist, enabling deployment of equipment with limited cash outflow and no immediate large capital expenditure required from company reserves.
The company plans CAPEX of Rs.170 crores for FY25, with Rs.22 crores already spent in Q1, funded through internal means and vendor financing.
No indications of equity fundraising or new debt issuance were disclosed during the call.

Order book

Yes

The company is involved in several government tenders, including a significant pending Rajasthan tender with over 1,200 collection centers; operationalizing would take 9-12 months post-win.
Rajasthan tender is currently under judicial review; company has fulfilled all obligations and awaits resolution.
Maharashtra tender includes 21 CTs implemented in Q1 FY25; plans to deploy additional 14 CTs and 5 MRI machines this fiscal year.
Other active contracts: Maharashtra (~15 years), Odisha (~12 years), Assam (~5 years), Madhya Pradesh (~12 years).
Pipeline includes projects in Andhra Pradesh and Southern regions; further tender participation ongoing.
Vendor financing arrangements exist to limit upfront CAPEX on new contracts.
The company targets a 25%-30% revenue growth with increasing EBITDA margins aided by both matured and new centers.

See what Krsnaa Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned CAPEX for FY25 is Rs.170 crores, with Rs.22 crores already spent in Q1.
CAPEX is mainly focused on radiology projects in Maharashtra and Madhya Pradesh, including deployment of CT scans and MRIs.
Maharashtra plans include operationalizing 21 CT centers with another 18 soon, plus installing seven more CT machines and five MRIs by year-end.
Madhya Pradesh MRI project involves installing five MRIs; two centers expected operational by year-end.
Vendor financing arrangements are in place for Rajasthan tender equipment, enabling asset deployment with minimal immediate cash outgo.
Retail expansion involves setting up 40 leased labs leveraging existing PPP infrastructure to grow consumer and B2B revenues.
The company is targeting to increase presence through the retail franchise by digital and offline channels without establishing new franchises but leveraging existing networks.

Track Krsnaa Diagnost. — get its next earnings analysis in your feed

How does Krsnaa Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisKrsnaa Diagnost.

Rev 3Mar 1

See where Krsnaa Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krsnaa Diagnost. rank in Healthcare Services?

Compare Krsnaa Diagnost. against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →